Prospective trial of Radiofrequency Catheter Ablation of High Dominant Frequencies after Pulmonary Vein Isolation in Non-paroxysmal Atrial Fibrillation

Prospective trial of Radiofrequency Catheter Ablation of High Dominant Frequencies after Pulmonary Vein Isolation in Non-paroxysmal Atrial Fibrillation - PAD-AF Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042543

Enrollment

440

Registered

2020-12-01

Start date

2020-09-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-paroxysmal Atrial Fibrillation

Interventions

ablation at high-DF sites after pulmonary vein ablation (PVI) pulmonary vein ablation (PVI) alone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)non-valvular non-paroxysmal atrial fibrillation(continuous AF duration more than 6 months) (2)Age between 20 and 80 years old at the time of obtaining consent (3)Those who have obtained written consent of their own free will with a full understanding of the research subject.

Exclusion criteria

Exclusion criteria: (1)other investigational study involvement (2)Mitral stenosis (3)artificial valve (4)Patients with cardiovascular events (stroke, myocardial infarction, heart failure requiring hospitalization) or bleeding requiring hospitalization within one month before registration (5)life expectancy within one year (6)LA thrombus (7)left atrial size>50 mm (8)prior AF ablation (9)Patients who cannot continue taking anticoagulants (10)pregnancy (11)thyroid disease (12)tumors (13)LVEF<50% (14)continuous AF duration more than 7 years (15)HCM,DCM (16)renal function<eGFR50ml/m/1.73m2dl

Design outcomes

Primary

Measure	Time frame
The atrial fibrillation freedom off antiarrhythmic drugs after ablation at high-DF sites after PVI of non-paroxysmal AF during 12 months of follow-up	—

Countries

Japan

Contacts

Public ContactKoji Kumagai

Tohoku Medical and Pharmaceutical University Department of Cardiovascular Medicine

pad-af@hosp.touhoku-mpu.ac.jp022-259-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026